Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Triple-blind, Placebo- and Positive-Controlled, Parallel Group Study of the Effect of Buprenorphine Delivered by the Buprenorphine Transdermal System (BTDS) at Doses up to 80 mcg/Hour and Naltrexone on ECG Intervals in Healthy Adult Subjects

NCT01999114 is registered in ClinicalTrials.gov with Purdue Pharma LP as lead sponsor.

NCT NCT01999114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01999114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Triple-blind, Placebo- and Positive-Controlled, Parallel Group Study of the Effect of Buprenorphine Delivered by the Buprenorphine Transdermal System (BTDS) at Doses up to 80 mcg/Hour and Naltrexone on ECG Intervals in Healthy Adult Subjects
Lead sponsor
Purdue Pharma LP
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2012
Completion date
October 31, 2012
Enrollment
328 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ecg effects